



VentriPoint Heart Analysis System Clinically Validated in Second Congenital Heart Disease Application

Thursday, January 05, 2012

SEATTLE, WASHINGTON--(Marketwire - Jan. 5, 2012) -

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

VentriPoint Diagnostics Ltd. (the "Corporation" or "VentriPoint") (TSX VENTURE:VPT) (PINKSHEETS:VPTDF) announced today the e-publication of an independent assessment of the VMS™ heart analysis system in a second congenital heart disease application, known as Systemic Right Ventricle. The clinical study on 25 patients was conducted by the research team at the Children's Hospital & Medical Center in Omaha, Nebraska lead by Dr. Shelby Kutty and appears in American Journal of Cardiology.

"The publication began by noting; "A 2-dimensional echocardiographic means for serial monitoring of the right ventricle (RV) would be of great value in this clinical setting." And concluded; "This study demonstrates the clinical feasibility of quantifying systemic RV volumes and function using VMS™ in adolescents and young adults with repaired d-transposition of great arteries".

"The company would like to thank Dr. Kutty and his team for the excellent study that they performed and for demonstrating this clinical application of the VMS™ for this patient population which requires lifelong frequent monitoring", said Dr. George Adams, CEO of VentriPoint. "The company continues to expand its menu of applications and will begin updating its regulatory approvals in Europe and Canada for this indication immediately. We believe that the market potential for congenital heart diseases is large and Systemic Right Ventricle VMS™ application is an important component as current imaging techniques are insufficient or too expensive to be used routinely."

The full article entitled "Echocardiographic Knowledge-Based Reconstruction For Quantification Of The Systemic Right Ventricle In Young Adults With Repaired D-Transposition Of Great Arteries" is available in preprint electronic form now on the journal's website at <http://www.ajconline.org/article/s0002-9149%2811%2903388-1/abstract> and will appear in print form shortly.

About Systemic Right Ventricle

The systemic right ventricle (RV) in congenital heart disease is susceptible to progressive dilation and dysfunction. There is a high incidence of heart failure in young adults with systemic RV, with mortality related to heart failure as high as 47% in symptomatic patients. Even in asymptomatic patients, a high frequency of RV dysfunction has been shown. Therefore, these patients require serial and lifelong follow-up of systemic RV function. Due to the dilation 3D ultrasound is often not possible. With the VMS™, the identification of entire endocardial borders is not necessary for reconstruction, a great advantage in these patients with a dilated RV and ultrasound window limitations.

About VentriPoint Diagnostics Ltd:

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS™ diagnostic tool and is pursuing the US-FDA approval through the 510(k) process.

Cautionary Note Regarding Forward-Looking Statements: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Ventripoint Diagnostics .

George Adams

President & CEO

Ph: (206) 283-0221

Fax: (206) 283-2309

info@ventripoint.com

www.ventripoint.com

The Howard Group Inc.

Peter Weichler/Dave Burwell

Investor Relations

Toll Free: 1-888-221-0915

Phone: (403) 221-0915

Info@howardgroupinc.com

www.howardgroupinc.com